Stockreport

Invivyd (IVVD) Announces Favorable Phase 3 Analysis for VYD2311 COVID-19 Treatment [Yahoo! Finance]

Invivyd, Inc.  (IVVD) 
PDF in its REVOLUTION clinical program, specifically regarding VYD2311, a monoclonal antibody candidate for COVID-19 prevention. A pre-specified analysis of the Phase 3 DECL [Read more]